BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

South Korea

Celltrion’s YUFLYMA® Granted Full FDA Interchangeability with Humira® Across All Dosage Forms

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] Cellt...

May 22, 2025 | News

SK Bioscience Wins Supreme Court Patent Battle Against Pfizer Over Pneumococcal Vaccine

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that it the Supreme C...

May 22, 2025 | News

IDT Biologika Ramps Up Global CDMO Expansion Following SK Bioscience Acquisition

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that IDT Biologika, a...

May 21, 2025 | News

Lunit Expands U.S. Footprint with AI-Powered Breast Cancer Screening at Over 200 Sites

Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imagi...

May 20, 2025 | News

Thermo Fisher Scientific Opens Cell and Gene Therapy Vision Center in South Korea

— Thermo Fisher Scientific, the world leader in serving science, has announced the official opening of its new Cell and Gene Therapy (CGT) Vision Cen...

May 15, 2025 | News

Agilent and Ubix Therapeutics Join Forces to Advance Targeted Cancer Therapies in South Korea

Research focuses on targeted protein degradation and antibody-drug conjugate as promising modalities for developing next-generation cancer therapies ...

May 15, 2025 | News

Hyundai ADM Bio Withdraws IND for Penetrium™/Docetaxel and Pivots to Immunotherapy Combinations

Hyundai ADM Bio announced the voluntary withdrawal of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating Pene...

May 14, 2025 | News

Connext Completes Phase 1 for CNT201, Eyes Phase 2 Launch and Expansion into Peyronie’s Disease

Conducted under U.S. FDA-cleared IND– Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease Connext, a clinical s...

May 09, 2025 | News

TiumBio’s Merigolix Shows Phase 2 Success in Asia for Uterine Fibroids

TiumBio (KRX: 321550.KQ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare a...

May 08, 2025 | News

SK Bioscience to Lead Korea’s Avian Influenza Vaccine Development Under KRW 5.25B Pandemic Preparedness Program

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it has bee...

May 07, 2025 | News

China Grants Full Approval to Everest Medicines’ NEFECON® as First and Only Etiological Treatment for IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

May 07, 2025 | Regulatory

AGC Biologics Partners with South Korea’s Novelty Nobility to Advance Bispecific Antibody Program Across Europe and Asia

Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites AGC Biologics, your friendly CDMO expert, an...

May 06, 2025 | News

S&E bio Receives MFDS Approval for Korea’s First Clinical Trial of Exosome-Based Stroke Therapy

S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food...

May 01, 2025 | News

Lotte Biologics Seals First ADC Manufacturing Deal to Launch Full-Scale US Production

Lotte Biologics has announced the signing of its first official contract manufacturing agreement at its newly expanded antibody-drug conjugate (ADC) produc...

April 25, 2025 | News

Stay Connected